Clinical Trial Detail

NCT ID NCT03313778
Title Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Moderna Therapeutics
Indications

Advanced Solid Tumor

bladder urothelial carcinoma

colorectal cancer

esophagus adenocarcinoma

melanoma

gastric adenocarcinoma

endometrial cancer

non-small cell lung carcinoma

lung small cell carcinoma

head and neck squamous cell carcinoma

Therapies

mRNA-4157 + Pembrolizumab

mRNA-4157

Age Groups: adult senior

Additional content available in CKB BOOST